Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1204 participants
OBSERVATIONAL
2013-10-18
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.
The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.
The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality of Life in Elderly Patients After Pancreatic Cancer Surgery
NCT06079229
Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer
NCT04406571
Prospective Monocentric Clinical-biological Database
NCT04136132
Management of Symptomatic Advanced Pancreatic Adenocarcinoma
NCT02979483
Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma
NCT04429490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pancreatic Adenocarcinoma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pancreatic adenocarcinoma histologically or cytologically proven
* primary diagnosis
* Agreed to participate
Exclusion Criteria
* Refused to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Departemental Vendee
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roger FAROUX, PH
Role: PRINCIPAL_INVESTIGATOR
Centre hospitalier départemental Vendée
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH de Jolimont
Jolimont, , Belgium
CH Gabriel Martin
Saint-Paul, La Réunion, France
CHIAP
Aix-en-Provence, , France
CH Angoulême
Angoulême, , France
CH d'Aubenas
Aubenas, , France
CH Auch
Auch, , France
CH Robert Ballanger
Aulnay-sous-Bois, , France
CH Avignon
Avignon, , France
CH Bagnols sur Ceze
Bagnols-sur-Cèze, , France
CH Bayeux
Bayeux, , France
CH Béziers
Béziers, , France
CH Blois
Blois, , France
CH Bourg en Bresse
Bourg-en-Bresse, , France
CH de Bourges
Bourges, , France
CH Nord Deux Sèvres
Bressuire, , France
CH Saint Camille
Bry-sur-Marne, , France
HPA Castres Mazamet
Castres, , France
CH Chambery
Chambéry, , France
CH Chartres
Chartres, , France
CH Chalons en champagne
Châlons-en-Champagne, , France
CH Haut Anjou
Château-Gontier, , France
CH Châteauroux
Châteauroux, , France
Ch Cholet
Cholet, , France
CH Compiègne Noyon
Compiègne, , France
CH sud francilien
Corbeil-Essonnes, , France
CH de Creil
Creil, , France
CHI Créteil
Créteil, , France
CH Dourdan
Dourdan, , France
CH Draguignan
Draguignan, , France
CH Dreux
Dreux, , France
CH Simone Veil
Eaubonne, , France
CH Forcilles
Férolles, , France
Chicas
Gap, , France
CH Gonesse
Gonesse, , France
Centre hospitalier départemental Vendée
La Roche-sur-Yon, , France
Centre Hospitalier de Lagny
Lagny-sur-Marne, , France
CH du Mans
Le Mans, , France
Lens
Lens, , France
Centre Hospitalier Côté de lumière
Les Sables-d'Olonne, , France
Hôpital des chanaux
Mâcon, , France
Centre Hospitalier de Meaux
Meaux, , France
CH Melun
Melun, , France
CHR de Mercy-Metz
Metz, , France
CHAM
Montargis, , France
CH Montauban
Montauban, , France
Centre Hospitalier Montelimar
Montélimar, , France
CH Montfermeil
Montfermeil, , France
CH Niort
Niort, , France
CHG Oloron
Oloron-Sainte-Marie, , France
CHR Orléans
Orléans, , France
CH François Mitterand
Pau, , France
Centre Hospitalier de Perpignan
Perpignan, , France
CHI Poissy Saint Germain
Poissy, , France
CH Pontoise
Pontoise, , France
CH de la région d'Annecy
Pringy, , France
CH Quimper
Quimper, , France
CH Roubaix
Roubaix, , France
Centre hospitalier Yves Le Foll
Saint-Brieuc, , France
CH de la Fontaine
Saint-Denis, , France
CH Saint Quentin
Saint-Quentin, , France
Centre Hospitalier de Bigorre
Tarbes, , France
CH Sainte Musse
Toulon, , France
CH Tourcoing
Tourcoing, , France
CH Valenciennes
Valenciennes, , France
CHBA de Vannes
Vannes, , France
CHIV Villeneuve Saint-Georges
Villeneuve-Saint-Georges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHD064-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.